The Effect of Shenfu Injection Combined with Sacubitril Valsartan Sodium in the Treatment of Intractable Heart Failure
Objective:To analyze the application effect of Shenfu Injection combined with Sacubitril Valsartan Sodium in the clinical treatment of intractable heart failure.Method:A total of 80 patients with intractable heart failure admitted to the Cardiovascular Department of Zibo Traditional Chinese Medicine Hospital from February 2020 to February 2023 were selected and randomly divided into two groups,with 40 cases in each group.The control group was treated with Sacubitril Valsartan Sodium,while the observation group was treated with Shenfu Injection in combination.The clinical efficacy,cardiac function and myocardial injury markers before and after treatment were compared between the two groups.Result:The total effective rate of the observation group was 92.50%,which was higher than 75.00%of the control group,the difference between groups was statistically significant(P<0.05).Three days before the start of treatment,there were no statistically significant differences in left ventricular ejection fraction(LVEF),left ventricular posterior wall thickness(LVPWT),interventricular septal thickness(IVST),left ventricular end systolic diameter(LVESD)and left ventricular end diastolic diameter(LVEDD)between the two groups(P>0.05),three days after treatment,the LVEF of the observation group was(74.91±4.26)%,which was higher than(65.57±2.74)%of the control group,LVPWT,IVST,LVESD and LVEDD were(8.19±0.21),(9.03±0.38),(31.32±1.77)and(49.33±1.71)mm,respectively,which were lower than(9.28±0.47),(10.60±0.60),(36.27±2.16)and(55.20±2.14)mm in the control group,with statistical significance(P<0.05).Three days before the start of treatment,there were no statistically significant differences in the levels of creatine kinase isoenzyme(CK-MB),growth and differentiation factor-15(GDF-15),copeptin(CPP)and brain natural peptide amino terminal precursor protein(NT-proBNP)between the two groups(P>0.05).Three days after treatment,the levels of CPP,CK-MB,NT-proBNP and GDF-15 in the observation group were(14.11±0.54)pmol/L,(15.31±1.26)μg/L,(490.62±15.55)ng/mL,(0.89±0.08)ng/mL,which were lower than(19.32±0.89)pmol/L,(19.09±1.34)μg/L,(544.42±17.25)ng/mL,(1.03±0.10)ng/mL in the control group,the differences between groups were statistically significant(P<0.05).Conclusion:In the clinical treatment of intractable heart failure,the combination of Shenfu Injection and Sacubitril Valsartan Sodium can alleviate myocardial injury,inhibit myocardial fibrosis,lower myocardial enzyme levels,improve cardiac function and prognosis,and has high therapeutic practicality.
国家科技期刊平台
NSTL
万方数据
